Treatment outcomes for muscle inflammation with rapid lung disease
Part of Bones, joints & muscles, Brain & nervous system, Lungs & breathing clinical trials.
This study looks at how well treatments work for people with muscle inflammation (myositis) that causes a fast-progressing lung condition. It may help doctors find better ways to manage this serious combination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years old or older
- You have been diagnosed with myositis (muscle inflammation) along with rapidly progressing interstitial lung disease (a lung condition that worsens quickly)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses advanced imaging to see how immunosuppressive medications (like mycophenolate or prednisone) affect lung scarring in patients with certain types of lung fibrosis. You would have imaging scans and breathing tests to track changes over time.
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
This study helps doctors identify early signs of lung scarring (fibrosis) in patients with autoimmune diseases like scleroderma, rheumatoid arthritis, and Sjögren's syndrome. By catching this early, researchers hope to better understand and treat these complications.
This trial looks at treatment strategies for people with idiopathic inflammatory myopathies, which are illnesses where the immune system attacks muscles. It may help improve how treatment is chosen and optimized for this group of conditions, but it specifically excludes several related muscle diseases.
This study follows people with inflammatory myositis over time to learn more about the condition. If you join, you may receive closer monitoring and contribute to research that could improve future treatments.
This trial looks at how the immune system and tiny organisms in the lungs may affect a rare condition called anti-MDA5 positive dermatomyositis, which can cause serious lung disease. It may help doctors understand why some patients get worse quickly and how to better treat them.
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.